ストックスクリーナーアプリを入手
174.41
2.08%
3.56
アフターアワーズ：
165.69
-8.72
-5.00%
前日終値:
$170.85
開ける：
$172.48
24時間の取引高:
242.26K
Relative Volume:
1.13
時価総額：
$5.02B
収益：
-
当期純損益:
$105.94M
株価収益率:
-118.65
EPS:
-1.47
ネットキャッシュフロー:
$-22.76M
1週間 パフォーマンス:
-1.02%
1か月 パフォーマンス:
-1.52%
6か月 パフォーマンス:
+8.26%
1年 パフォーマンス:
+42.78%
1日の値動き範囲:
$170.65
$175.96
1週間の範囲:
$163.66
$176.49
52週間の値動き範囲:
$93.95
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
名前
Krystal Biotech Inc
セクター
電話
(412) 586-5830
住所
2100 WHARTON STREET, PITTSBURGH, PA
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 開始されました | Citigroup | Buy |
| 2023-09-07 | 開始されました | Berenberg | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2023-02-28 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-25 | ダウングレード | Goldman | Buy → Neutral |
| 2022-01-18 | 開始されました | BofA Securities | Buy |
| 2021-07-20 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-18 | 開始されました | B. Riley FBR | Buy |
| 2020-06-04 | 開始されました | Evercore ISI | Outperform |
| 2019-09-24 | 開始されました | Goldman | Neutral |
| 2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-24 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-06-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-30 | 開始されました | Guggenheim | Buy |
| 2018-09-11 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Krystal Biotech Inc (KRYS) 最新ニュース
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction - Yahoo Finance
Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $206.00 at Citigroup - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Announces Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2024 Earnings Call Transcript - Insider Monkey
Krystal Biotech Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Krystal Biotech Inc (KRYS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Krystal Biotech Faces Challenges in Scaling VYJUVEK Production Amid Regulatory Hurdles - TipRanks
Earnings call: Krystal Biotech reports robust Q3 2024 results By Investing.com - Investing.com Nigeria
Krystal Biotech Reports Strong Q3 2024 Performance - TipRanks
Krystal Biotech (NASDAQ:KRYS) Shares Gap DownHere's Why - MarketBeat
Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Krystal Biotech earnings missed by $0.08, revenue topped estimates - Investing.com UK
Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Krystal Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Are Options Traders Betting on a Big Move in Krystal Biotech (KRYS) Stock? - MSN
Where are the Opportunities in (KRYS) - Stock Traders Daily
Earnings To Watch: Krystal Biotech Inc (KRYS) Reports Q3 2024 Re - GuruFocus.com
Earnings To Watch: Krystal Biotech Inc (KRYS) Reports Q3 2024 Results - Yahoo Finance
Krystal Biotech (KRYS) Set to Announce Quarterly Earnings on Monday - MarketBeat
Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth - MSN
Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024 - The Manila Times
Hennion & Walsh Asset Management Inc. Cuts Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
(KRYS) Proactive Strategies - Stock Traders Daily
Everence Capital Management Inc. Invests $557,000 in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK(TM) (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa - InvestorsObserver
All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy - MSN
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
State Street Corp's Strategic Acquisition in Krystal Biotech Inc - Yahoo Finance
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On - Seeking Alpha
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Shaker Investments LLC OH Acquires Shares of 2,920 Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
When (KRYS) Moves Investors should Listen - Stock Traders Daily
US Growth Stocks With High Insider Ownership - Simply Wall St
Bank of Montreal Can Purchases Shares of 2,936 Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy? - Benzinga
Handelsbanken Fonder AB Has $17.24 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech (KRYS) Stock Price, News & Analysis - MarketBeat
Krystal Biotech And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
Teachers Retirement System of The State of Kentucky Takes $555,000 Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech, Inc. : Will it go even higher? - Marketscreener.com
How the (KRYS) price action is used to our Advantage - Stock Traders Daily
Krystal Biotech shares reiterate buy rating, price target on strong fundamentals - Investing.com India
Vanguard Personalized Indexing Management LLC Takes Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Sei Investments Co. - MarketBeat
Driehaus Capital Management LLC Buys 8,547 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Amalgamated Bank Has $1.39 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech (NASDAQ: KRYS)Related Research - Intelligent Investor
54,656 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Acquired by Public Sector Pension Investment Board - MarketBeat
Top investors say Krystal Biotech Inc (KRYS) ticks everything they need - SETE News
Avoro Capital Advisors LLC Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech Inc (KRYS) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):